The Marque The Marque
The Marque
About Services Profiles Press Contact
Reshma’s Profile > News Archive

Reshma’s News Archive

The News Archive for Reshma Kewalramani

Reshma’s News Archive

The News Archive for Reshma Kewalramani

Reshma Kewalramani

CEO & President

Vertex Pharmaceuticals
Boston, MA, USA
1 May 2023 | India New England News

AIF Boston Gala Raises Over $1.1M, Honors Vertex & CRISPR CEOs Reshma Kewalramani & Samarth Kulkarni

The gala, held on Saturday, April 29th, and was attended by 440 guests – the highest that the venue has seen and saw a sizable “young American Indian” participation with several tables hosting young professionals below the age of 45 years from the Greater Boston area.

21 Apr 2023 | Harvard Business School

Harvard Business School Honors Five Graduates with 2023 Alumni Achievement Award

Reshma Kewalramani, MD will be one of five recipients of the School's highest honor, which is given to alumni who are leaders in their fields and who exemplify the mission, highest standards, and values of the School. Recipients will be honored at the School’s Commencement ceremony on May 25, 2023.

31 Mar 2023 | India New England News

AIF to Honor Life Sciences Icons Reshma Kewalramani and Samarth Kulkarni

American India Foundation will honor life sciences icons Reshma Kewalramani and Samarth Kulkarni at its 17th Annual New England Gala on April 29, 2023 at the Renaissance Boston Waterfront Hotel.

22 Sep 2022 | Asian American Business Development Center

21st Anniversary of Outstanding 50 Asian Americans in Business Award

Reshma Kewalramani was honored with this award that recognizes Asian American entrepreneurs, professionals and corporate executives who are engaged in a wide range of business interests and have a role in driving the U.S. economy. 

11 Jul 2022 | Businesswire

Vertex to Acquire ViaCyte, Goal of Accelerating its Potentially Curative VX-880 Diabetes Programs

Reshma Kewalramani sees this acquisition as an opportunity for Vertex to expand its capabilities in its current stem cell-based programs. 

Load More